Views

CrossRef citations to date

Altmetric

Letters to the Editor

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient

Aitomi Bittnera Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyCorrespondence[email protected]

https://orcid.org/0000-0001-6434-0950

Josefine Radkeb Berlin Institute of Health (BIH), Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;d Department of Neuropathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Dennis Euriche Department of Surgery, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Edzard Wienerf Institute of Neuroradiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Sophy Denkera Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany

Ioannis Anagnostopoulosg Institute of Pathology, University of Würzburg, Würzburg, Germany

Il-Kang Naa Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;b Berlin Institute of Health (BIH), Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;h Experimental and Clinical Research Center (ECRC), Berlin, Germany;i BIH Centre for Regenerative Therapies, Berlin, Germany

Frank L. Heppnerb Berlin Institute of Health (BIH), Berlin, Germany;d Department of Neuropathology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;j Cluster of Excellence, NeuroCure, Berlin, Germany;k German Center for Neurodegenerative Diseases (DZNE), Berlin, Germany

Lars Bullingera Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;b Berlin Institute of Health (BIH), Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;l Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany

Clemens A. Schmitta Department of Hematology, Oncology and Tumor Immunology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany;c German Cancer Consortium (DKTK), Berlin, Germany;l Max-Delbrück-Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany;m Department of Hematology and Oncology, Kepler University Hospital, Johannes Kepler University, Linz, Austria

show all

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors thank Randi Koll for excellent technical assistance.

Author contributions

A.B. and C.A.S. wrote the manuscript; A.B. and J.R. made the figures; all authors were involved in the clinical management of the reported patient, revised the manuscript and approved the final version.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Correction Statement

This article has been republished with minor changes. These changes do not impact the academic content of the article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient

Information for

Open access

Opportunities

Help and information

Cerebral EBV-positive PTLD controlled by PD-1 checkpoint blockade in a liver transplant patient

Acknowledgements

Author contributions

Disclosure statement

Correction Statement

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature